Exploratory Study of Pagoclone in Men With Premature Ejaculation.
NCT ID: NCT00370981
Last Updated: 2013-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2006-07-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation
NCT07047404
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT00143117
PSD502 in Subjects With Premature Ejaculation
NCT03578783
Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation
NCT01798667
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
NCT00219635
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.15 mg
pagoclone
0.30 mg
pagoclone
0.60 mg
pagoclone
PBO
pagoclone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pagoclone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 to 55 yrs old
* In a Stable relationship with one woman for at least 6 months
18 Years
55 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Endo Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology Centers of Alabama, PC
Homewood, Alabama, United States
SD Uro-Research
San Diego, California, United States
Urology Research Options
Aurora, Colorado, United States
Urology Associates, PC
Denver, Colorado, United States
Connecticut Clinical Research Center
Waterbury, Connecticut, United States
South Florida Medical Research
Aventura, Florida, United States
Northeast Indiana Research, LLC
Fort Wayne, Indiana, United States
Davis Clinic, PC
Indianapolis, Indiana, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
AccuMed Research Associates
Garden City, New York, United States
Urological Surgeons of Long Island, PC
Garden City, New York, United States
Center for Urologic Research of WNY
Williamsville, New York, United States
Metrolina Urology Clinic
Charlotte, North Carolina, United States
Wake Research Associates, LLC
Raleigh, North Carolina, United States
Johnny B. Roy, MD Private Practice
Edmond, Oklahoma, United States
Mobley Research Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IP456-040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.